康莱特联合吉西他滨治疗进展期胰腺癌的疗效观察

目的：观察康莱特联合吉西他滨治疗进展期胰腺癌的临床疗效、临床获益反应和不良反应.方法：40例未接受过全身化疗的进展期胰腺癌患者,至少接受2个周期的康莱特联合吉西他滨化疗方案.康莱特200ml静滴,每天1次,吉西他滨1000mg/m2,第1天和第8天,每21天为一个周期.结果：40例患者中3例临床缓解,13例部分缓解,11例稳定.总的疾病控制率为67.5％.疼痛缓解率为88.6％.骨髓抑制发生率为37.5％.无化疗相关死亡.结论：康莱特联合吉西他滨治疗进展期胰腺癌可提高疾病控制率,改善患者生活质量,减轻疼痛,减少不良反应的发生.

Efficacy of kanglaite combined with gemcitabine in patients with advanced pancreatic cancer

Objective：To evaluate the efficacy,clinical benefits and adverse reactions of kanglaite combined with gemcitabine for advanced pancreatic cancer. Methods：All 40 patients with advanced pancreatic cancer were treated with kanglaite 200ml/d, and gemcitabine 1000mg/m2 on first day and eighth day （repeated every 21 days）. All pa- tients received over two cycles of this regimen. Results：Among 40 patients disease control rate was 67.5%, including 3 CR, 13 PR and 11 SD. The rate of pain relief was 88.6%. Myelosuppression rate was 37.5%. No chemotherapy - related death occurred. Conclusion：Kanglaite in combination with gemcitabine can be used for the treatment of ad- vanced pancreatic cancer. It can improve efficacy and the quality of life, relieve pain, and reduce the adverse reactions of chemotherapy.